Summary
Renal cell cancer is the main malignant tumour of the kidney and has an increasing incidence. This type of tumour has a poor prognosis and shows intrinsic resistance to several anti-cancer drugs. The CYP3A P450 family, which consists of three closely related forms, is involved in the oxidative activation and deactivation of a variety of carcinogens and several anti-cancer drugs. In this study the presence and cellular localization of CYP3A has been investigated using a combination of immunohistochemistry, immunoblotting and reverse transcriptase polymerase chain reaction (RT-PCR) in renal cell cancer and corresponding normal kidney. CYP3A was consistently expressed in both renal call cancer and in normal kidney. In renal cell cancer, CYP3A was localized to tumour cells and in normal kidney the predominant cellular localization of CYP3A was to proximal tubular epithelial cells. RT-PCR showed that both CYP3A5 mRNA and CYP3A7 mRNA were consistently present in both tumour and normal samples, while CYP3A4 mRNA was present in 65% of tumours and 90% of normal samples. This study indicates that individual members of the CYP3A family are expressed in renal cell cancer. The presence of CYP3A in renal cell cancer might be important in the metabolic potentiation as well as the detoxification of chemotherapeutic agents used to renal cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anttila, S., Hukkanen, J., Hakkola, J., Stjernvall, T., Beaune, P., Edwards, R. J., Boobis, A. R., Pelkonen, O. & Raunio, H. (1997). Expression and localization of CYP3A4 and CYPA5 in human lung. Am J Respir Cell Mol Biol 16: 242–249.
Bradford, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 72: 248–254.
Capdevila, J., Falck, J. R. & Estabrook, R. W. (1992). Cytochrome P450 and the arachidonate cascade. FASEB J 6: 731–736.
Chang, T. K. H., Weber, G. F., Crespi, C. L. & Waxman, D. J. (1993). Differential activation of cyclophosphamide and ifosphamide by cytochrome P450 2B and cytochrome P450 3A in human liver-microsomes. Cancer Res 53: 5629–5637.
Chapman, A. E. & Goldstein, L. J. (1995). Multiple drug resistance; biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol 22: 17–28.
Fritz, P., Behrle, E., Beaune, P., Eichelbaum, M. & Kroemer, H. K. (1993). Differential expression of drug metabolising enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P450 3A and glutathione S-transferase. Histochemistry 99: 443–451.
Gervot, L., Carrière, V., Costet, P., Cugnenc, P-H, Berger, A., Beaune, P. H. & de Waziers, I. (1996). CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ Toxicol Pharmacol 2: 381–388.
Gonzalez, F. J. & Gelboin, H. V. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26: 165–183.
Guengerich, F. P. (1992). Metabolic activation of carcinogens. Pharmacol Ther 54: 17–62.
Haehner, B. D., Gorski, J. C., Vandenbranden, M., Wrighton, S. A., Janarden, S. K., Watkins, P. B. & Hall, S. D. (1996). Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50: 52–59.
Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. & Collins, J. M. (1994). Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026–4035.
Janardan, S. K., Lown, K. S., Schiedlinrern, P., Thummel, K. E. & Watkins, P. B. (1996). Selective expression of CYP3A5 and not CYP3A4 in human blood. Pharmacogenetics 6: 379–385.
Kawajiri, K. & Fujii-Kuriyama, Y. (1991). P450 and human cancer. Jpn J Cancer Res 82: 1325–1335.
Kitada, M. & Kamataki, T. (1994). Cytochrome P450 in human fetal liver: significance and fetal specific expression. Drug Metab Dispos 26: 305–323.
Kivistö, K. T., Kroemer, H. K. & Eichelbaum, M. (1995a). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40: 523–530.
Kivistö, K. T., Fritz, P., Linder, A., Friedel, G., Beaune, P. & Kroemer, H. K. (1995b). Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol 103: 25–29.
Kivistö, K. T., Griese, E-U, Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P. & Kroemer, H. K. (1996). Expression of cytochrome P450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Arch Pharmacol 353: 207–212.
Kovacs, G., Akhtar, M., Beckwith, B., Gugert, P., Cooper, C. S., Dleahunt, B., Eble, J. N., Fleming, S., Ljunberg, B., Medeiros, L. J., Moch, H., Reuter, V. E., Ritz, E., Roos, G., Schmidt, D., Srigley, J. R., Störkel, S., Van Den Berg, E. & Zbar, B. (1997). The Heidelberg classification of renal cell tumours. J Pathol 183: 131–133.
McFadyen, M. C. E., Melvin, W. T. & Murray, G. I. (1998). Regional distribution of individual forms of cytochrome P450 mRNA in normal human brain. Biochem Pharmacol 55: 825–830.
McKay, J. A., Weaver, R. J., Murray, G. I., Ewen, S. W. B., Melvin, W. T. & Burke, M. D. (1995). Expression of microsomal epoxide hydrolase in normal and neoplastic human kidney. J Histochem Cytochem 43: 615–620.
McKinnon, R. A., Burgess, W. M., Hall, PdelaM, Roberts-Thomson, S. J., Gonzalez, F. J. & McManus, M. E. (1995). Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36: 259–267.
Massaad, L., de Waziers, I., Ribrag, V., Janot, F., Beaune, P. H., Morizet, J., Gouyette, A. & Chabot, G. G. (1992). Comparison of mouse and human colon tumors with regard to phase 1 and phase II drug-metabolizing enzyme systems. Cancer Res 52: 6567–6575.
Motzer, R. J., Bander, N. H. & Nanus, D. M. (1996). Renal cell carcinoma. N Engl J Med 335: 865–875.
Murray, G. I., Barnes, T. S., Sewell, H. F., Ewen, S. W. B., Melvin, W. T., Shaw, P. M., Fowler, J. & Burke, M. D. (1987). Cytochrome P450 localisation in normal human adult and foetal liver by immunocytochemistry using a monoclonal antibody against human cytochrome P450. Histochem J 19: 537–545.
Murray, G. I., Barnes, T. S., Sewell, H. F., Ewen, S. W. B., Melvin, W. T. & Burke, M. D. (1988). The immunocytochemical localisation and distribution of cytochrome P450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P450. Br J Clin Pharmacol 25: 465–475.
Murray, G. I., Weaver, R. J., Paterson, P. J., Ewen, S. W. B., Melvin, W. T. & Burke, M. (1993). Expression of xenobiotic metabolising enzymes in breast cancer. J Pathol 169: 347–353.
Murray, G. I., Pritchard, S., Melvin, W. T. & Burke, M. D. (1995). Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Letts 364: 79–82.
Murray, G. I., Taylor, M. C., McFadyen, M. C., McKay, J. A., Greenlee, W. F., Burke, M. D. & Melvin, W. T. (1997). Tumour specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026–3031.
Murray, G. I., Taylor, M. C., Burke, M. D. & Melvin, W. T. (1998). Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer 77: 1040–1044.
Nebert, D. W. (1994). Drug-metabolizing-enzymes in ligand-modulated transcription. Biochem Pharmacol 47: 25–37.
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, J. M., Estabrook, R. W., Gunsalus, I. C. & Nebert, D. W. (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1–42.
Patterson, L. H. (1993). Rationale for the use of N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive drugs. Cancer Metast Rev 12: 119–234.
Roberts-Thomson, S. J., McManus, M. E., Tukey, R. H., Gonzalez, F. J. & Holder, G. M. (1995). Metabolism of polycyclic aza-aromatic carcinogens catalyzed by four expressed human cytochromes P450. Cancer Res 55: 1052–1059.
Sarabia, S. F., Zhu, B. T., Kurosawa, T., Tohma, M. & Liehr, J. G. (1997). Mechanism of cytochrome P450-catalyzed aromatic hydroxylation of estrogens. Chem Res Toxicol 10: 767–771.
Schuetz, E. G., Schuetz, J. D., Grogan, W. M., Naray-Fejes-Toth, A., Fejes-Toth, G., Raucy, J., Guzelian, P., Gionela, K. & Watlington, C. O. (1992). Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 294: 206–214.
Schuetz, J. D., Beach, D. L. & Guzelian, P. S. (1994). Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4: 11–20.
Shaw, P. M., Barnes, T. S., Cameron, D., Engeset, J., Melvin, W. T., Omar, G., Petrie, J. C., Rush, W. R., Snyder, C. P., Whiting, P. H. & Burke, M. D. (1989). Purification and characterization of an anticonvulsant-induced human cytochrome P450 catalysing cyclosporin metabolism. Biochem J 262: 653–663.
Stadler, W. & Vogelzang, N. J. (1993). Human renal cancer carcinogenesis; a review of recent advances. Annal Oncol 4: 451–462.
Walker, D., Flinois, J. P., Monkman, S. C., Beloc, C., Boddy, A. V., Cholerton, S., Daly, A. K., Lind, M. J., Pearson, A. D. J., Beaune, P. H. & Idle, J. R. (1994). Identification of the major human hepatic cytochrome P450 involved in activation and n-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157–1160.
Yagoda, A., Abi-Rached, B. & Petrylak, D. (1995). Chemotherapy for advanced renal cell carcinoma. Semin Oncol 22: 42–60.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Murray, G., McFadyen, M., Mitchell, R. et al. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79, 1836–1842 (1999). https://doi.org/10.1038/sj.bjc.6690292
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690292
Keywords
This article is cited by
-
Molecular targeting of renal cell carcinoma by an oral combination
Oncogenesis (2020)
-
The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance
British Journal of Cancer (2017)
-
The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation
Clinical Pharmacokinetics (2014)
-
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer
Cancer Gene Therapy (2009)
-
Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model
Cancer Gene Therapy (2007)